Physician profile
Peter Hu
NPI 1194066266
$6,009.79
in general payments reported to CMS, 2019-2025
22 companies · $2,355 in 2025
The $2,355 reported for 2025 was more than what 93% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $411 · 2022: $881 · 2023: $1,289 · 2024: $1,074 · 2025: $2,355.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,529 · Education: $189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,529.41 |
| Education | $188.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $1,235.10 | 2021-2025 | Opzelura |
| Genzyme Corporation | $591.57 | 2022-2025 | |
| Arcutis Biotherapeutics, INC. | $549.61 | 2023-2025 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $504.37 | 2023-2025 | Dupixent |
| Leo Pharma INC. | $459.81 | 2021-2025 | Adbry, Anzupgo |
| Dermavant Sciences, INC. | $446.03 | 2023-2024 | Vtama |
| Abbvie INC. | $438.11 | 2021-2025 | |
| Pfizer INC. | $413.73 | 2021-2025 | |
| Amgen INC. | $404.75 | 2023-2025 | Otezla, Otezla |
| Janssen Biotech, INC. | $229.22 | 2023-2025 | Tremfya, Stelara, Simponi Aria |
| E.R. Squibb & Sons, L.L.C. | $124.64 | 2022-2025 | Sotyktu |
| Organon LLC | $87.13 | 2025 | |
| Ucb, INC. | $84.70 | 2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $83.32 | 2023-2025 | |
| Cipher Pharmaceuticals US LLC | $77.93 | 2025 | Natroba, Spinosad |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Journey Medical Corporation | $70.49 | 2022 | |
| Galderma Laboratories, L.P. | $65.75 | 2021 | |
| Sun Pharmaceutical Industries INC. | $42.40 | 2023 | Ilumya |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $39.85 | 2022-2023 | Jublia |
| Botanix Sb INC | $26.12 | 2025 | Sofdra |
| Allergan, INC. | $21.42 | 2021 | |
| Lilly USA, LLC | $13.74 | 2024 | Olumiant, Taltz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Hu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.